Vaxxas

Nanopatch™ technology developed by Professor Mark Kendall could have a global impact by improving vaccines in overcoming key limitations of the needle and syringe. These include reducing a vaccine dose – by targeting to the skin’s immune system rather than a needle into muscle – and removing the need for vaccine refrigeration, because the vaccine is formulated in dry form.